文献速递乳腺癌放疗

高危乳腺癌新辅助放化疗中影响病理完全缓解与肿瘤退缩的因素

Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer.
PubMed 文献 · Radiat Oncol · 2024-07-31

回顾性分析341例1990至2003年接受新辅助放疗和新辅助全身治疗的高危乳腺癌患者,病理完全缓解(pCR)率为31%、原发肿瘤完全缓解(bpCR)率为39%。多因素分析显示切除类型、乳腺癌亚型、原发肿瘤分期及放疗至手术间隔影响pCR,放疗剂量超过60 Gy未提高缓解率。

要点

  • 341例高危乳腺癌患者中pCR率为31%,原发肿瘤完全缓解(bpCR)率为39%。
  • 多因素分析显示切除类型、乳腺癌亚型、原发肿瘤分期及放疗至手术间隔是pCR的影响因素。
  • 放疗剂量超过60 Gy未带来更高的缓解率。

核心结论

  • 新辅助全身治疗联合新辅助放疗后与pCR相关的因素与单纯新辅助全身治疗后已知因素相似。
  • 放疗至手术间隔较长可能与较高的pCR率相关。
  • 剂量递增超过60 Gy未导致更高的缓解率。

研究设计与样本

  • 回顾性分析1990至2003年间接受新辅助放疗和新辅助全身治疗的341例患者(cT1-cT4/cN0-N+)。
  • 新辅助放疗照射乳腺并多数照射锁骨上/下淋巴结,联合电子线或近距离放疗推量。
  • 新辅助全身治疗采用不同方案,与放疗序贯或同期进行。
  • 采用单因素和多因素回归分析评估不同亚组和治疗方式对pCR(ypT0/Tis且ypN0)及原发肿瘤完全缓解(ypT0/Tis;bpCR)的影响。
  • 采用受试者工作特征(ROC)分析评估放疗至切除间隔及放疗剂量。

主要发现

  • 341例患者中,pCR和bpCR分别达到31%和39%。
  • 多因素分析显示pCR率受切除类型、乳腺癌亚型、原发肿瘤分期及放疗至手术间隔影响。
  • bpCR的单因素分析显示年龄、切除类型、乳腺癌亚型、临床肿瘤分期和分级为显著因素。
  • 多因素分析中切除类型、亚型和临床肿瘤分期仍显著。
  • 肿瘤放疗剂量和放疗至手术间隔不是pCR的显著因素;但当治疗因素加入模型时,较长的放疗至切除间隔是pCR的显著预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathological complete response (pCR) is a well-established prognostic factor in breast cancer treated with neoadjuvant systemic therapy (naST). The determining factors of pCR are known to be intrinsic subtype, proliferation index, grading, clinical tumor and nodal stage as well as type of systemic therapy. The addition of neoadjuvant radiotherapy (naRT) to this paradigm might improve response, freedom from disease, toxicity and cosmetic outcome compared to adjuvant radiotherapy. The factors for pCR and primary tumor regression when neoadjuvant radiation therapy is added to chemotherapy have not been thoroughly described. METHODS: We performed a retrospective analysis of 341 patients (cT1-cT4/cN0-N+) treated with naRT and naST between 1990 and 2003. Patients underwent naRT to the breast and mostly to the supra-/infraclavicular lymph nodes combined with an electron or brachytherapy boost. NaST was given either sequentially or simultaneously to naRT using different regimens. We used the univariate and multivariate regression analysis to estimate the effect of different subgroups and treatment modalities on pCR (ypT0/Tis and ypN0) as well as complete primary tumor response (ypT0/Tis; bpCR) in our cohort. Receiver operating characteristic (ROC) analysis was performed to evaluate the interval between radiotherapy (RT) and resection (Rx) as well as radiotherapy dose. RESULTS: Out of 341 patients, pCR and pbCR were achieved in 31% and 39%, respectively. pCR rate was influenced by resection type, breast cancer subtype, primary tumor stage and interval from radiation to surgery in the multivariate analysis. Univariate analysis of bpCR showed age, resection type, breast cancer subtype, clinical tumor stage and grading as significant factors. Resection type, subtype and clinical tumor stage remained significant in multivariate analysis. Radiation dose to the tumor and interval from radiation to surgery were not significant factors for pCR. However, when treatment factors were added to the model, a longer interval from radiotherapy to resection was a significant predictor for pCR. CONCLUSIONS: The factors associated with pCR following naST and naRT are similar to known factors after naST alone. Longer interval to surgery might to be associated with higher pCR rates. Dose escalation beyond 60 Gy did not result in higher response rates.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Haussmann J, Budach W, Nestle-Krämling C, et al. Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer. Radiat Oncol. 2024. PMID: 39085866. doi:10.1186/s13014-024-02450-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。